MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

36.29 2.69

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

36.17

Максимум

36.42

Ключови измерители

By Trading Economics

Приходи

33M

-48M

Продажби

-2.6M

106M

EPS

-0.45

Марж на печалбата

-45.487

Служители

1,869

EBITDA

19M

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+55.77% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

498M

3.9B

Предишно отваряне

33.6

Предишно затваряне

36.29

Настроения в новините

By Acuity

50%

50%

113 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.07.2025 г., 23:55 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6.07.2025 г., 22:35 ч. UTC

Придобивния, сливания и поглъщания

South32 Expects to Complete Transaction in Late 2025

6.07.2025 г., 22:35 ч. UTC

Придобивния, сливания и поглъщания

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6.07.2025 г., 22:34 ч. UTC

Придобивния, сливания и поглъщания

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5.07.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 15:57 ч. UTC

Пазарно говорене

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4.07.2025 г., 15:49 ч. UTC

Пазарно говорене

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Received All Required Authorizations

4.07.2025 г., 15:48 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4.07.2025 г., 15:47 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Agreement Was Announced on Dec. 19

4.07.2025 г., 15:47 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4.07.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4.07.2025 г., 14:30 ч. UTC

Придобивния, сливания и поглъщания

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4.07.2025 г., 13:53 ч. UTC

Пазарно говорене

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4.07.2025 г., 13:41 ч. UTC

Пазарно говорене

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4.07.2025 г., 13:41 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.07.2025 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 12:37 ч. UTC

Пазарно говорене

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4.07.2025 г., 12:37 ч. UTC

Пазарно говорене

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

55.77% нагоре

12-месечна прогноза

Среден 56.7 USD  55.77%

Висок 75 USD

Нисък 38.2 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

113 / 375 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.